Sue-Anne McLachlan1, Richard J Fisher2, John Zalcberg2, Michael Solomon3, Bryan Burmeister4, David Goldstein5, Trevor Leong2, Stephen P Ackland6, Joseph McKendrick7, Bev McClure8, John Mackay2, Samuel Y Ngan2. 1. Peter MacCallum Cancer Centre, Australia; St Vincent's Hospital, Fitzroy, Australia; The University of Melbourne, Parkville, Australia. Electronic address: sue-anne.mclachlan@svhm.org.au. 2. Peter MacCallum Cancer Centre, Australia; The University of Melbourne, Parkville, Australia. 3. Royal Prince Alfred Hospital, Newtown, Australia; University of Sydney, Sydney, Australia. 4. Princess Alexandra Hospital, Woolloongabba, Australia; The University of Queensland, Brisbane, Australia. 5. Prince of Wales Hospital, Randwick, Australia; The University of New South Wales, Kensington, Australia. 6. Calvary Mater Hospital, Newcastle, Australia; The University of Newcastle, Callaghan, Australia. 7. Box Hill Hospital, Box Hill, Australia; Monash University, Clayton, Australia. 8. Peter MacCallum Cancer Centre, Australia.
Abstract
PURPOSE: To assess health-related quality of life (HRQOL) in patients participating in a randomised trial ofneoadjuvant short course radiation (SC) or long course chemoradiation (LC) for operable rectal cancer. PATIENTS AND METHODS: Eligible patients with T3N0-2M0 rectal cancer completed the European Organisation for Research and Treatment of Cancer quality of life questionnaire (QLQ-C30) and the colorectal cancer specific module (QLQ C38) at randomisation and 1, 2, 3, 6, 9 and 12 months later. RESULTS: Of 326 patients randomised, 297 (SC 143, LC 154) were eligible for completion of HRQOL questionnaires. Baseline scores were comparable across the SC and LC groups. Patients reported low scores on sexual functioning and sexual enjoyment. Defaecation problems were the worst of the symptoms at baseline. Surgery had the most profoundly negative effect on HRQOL, seen in both the SC and LC treatment groups to the same extent. The most severely affected domains were physical function and role function and the most severely affected symptoms were fatigue, pain, appetite, weight loss and male sexual problems. Most domains and symptoms returned to baseline levels by 12 months apart from body image, sexual enjoyment and male sexual problems. Future perspective was better than prior to treatment. CONCLUSION: There is no overall difference in HRQOL between SC and LC neoadjuvant treatment strategies, in the first 12 months, after surgery. In the immediate postoperative period HRQOL was adversely affected in both groups but for the most part was temporary. Some residual sexual functioning concerns persisted at 12 months.
RCT Entities:
PURPOSE: To assess health-related quality of life (HRQOL) in patients participating in a randomised trial of neoadjuvant short course radiation (SC) or long course chemoradiation (LC) for operable rectal cancer. PATIENTS AND METHODS: Eligible patients with T3N0-2M0 rectal cancer completed the European Organisation for Research and Treatment of Cancer quality of life questionnaire (QLQ-C30) and the colorectal cancer specific module (QLQ C38) at randomisation and 1, 2, 3, 6, 9 and 12 months later. RESULTS: Of 326 patients randomised, 297 (SC 143, LC 154) were eligible for completion of HRQOL questionnaires. Baseline scores were comparable across the SC and LC groups. Patients reported low scores on sexual functioning and sexual enjoyment. Defaecation problems were the worst of the symptoms at baseline. Surgery had the most profoundly negative effect on HRQOL, seen in both the SC and LC treatment groups to the same extent. The most severely affected domains were physical function and role function and the most severely affected symptoms were fatigue, pain, appetite, weight loss and male sexual problems. Most domains and symptoms returned to baseline levels by 12 months apart from body image, sexual enjoyment and male sexual problems. Future perspective was better than prior to treatment. CONCLUSION: There is no overall difference in HRQOL between SC and LC neoadjuvant treatment strategies, in the first 12 months, after surgery. In the immediate postoperative period HRQOL was adversely affected in both groups but for the most part was temporary. Some residual sexual functioning concerns persisted at 12 months.
Authors: An Ngo-Huang; Nathan H Parker; Xuemei Wang; Maria Q B Petzel; David Fogelman; Keri L Schadler; Eduardo Bruera; Jason B Fleming; Jeffrey E Lee; Matthew H G Katz Journal: Langenbecks Arch Surg Date: 2017-07-15 Impact factor: 3.445
Authors: Wang Qiaoli; Huang Yongping; Xiong Wei; Xu Guoqiang; Ju Yunhe; Liu Qiuyan; Li Cheng; Guo Mengling; Li Jiayi; Xiong Wei; Yang Yi Journal: Int J Colorectal Dis Date: 2019-11-19 Impact factor: 2.571
Authors: Mauro Podda; Patricia Sylla; Gianluca Baiocchi; Michel Adamina; Vanni Agnoletti; Ferdinando Agresta; Luca Ansaloni; Alberto Arezzo; Nicola Avenia; Walter Biffl; Antonio Biondi; Simona Bui; Fabio C Campanile; Paolo Carcoforo; Claudia Commisso; Antonio Crucitti; Nicola De'Angelis; Gian Luigi De'Angelis; Massimo De Filippo; Belinda De Simone; Salomone Di Saverio; Giorgio Ercolani; Gustavo P Fraga; Francesco Gabrielli; Federica Gaiani; Mario Guerrieri; Angelo Guttadauro; Yoram Kluger; Ari K Leppaniemi; Andrea Loffredo; Tiziana Meschi; Ernest E Moore; Monica Ortenzi; Francesco Pata; Dario Parini; Adolfo Pisanu; Gilberto Poggioli; Andrea Polistena; Alessandro Puzziello; Fabio Rondelli; Massimo Sartelli; Neil Smart; Michael E Sugrue; Patricia Tejedor; Marco Vacante; Federico Coccolini; Justin Davies; Fausto Catena Journal: World J Emerg Surg Date: 2021-07-02 Impact factor: 5.469
Authors: Emma B Holliday; Andrew Hunt; Y Nancy You; George J Chang; John M Skibber; Miguel A Rodriguez-Bigas; Brian K Bednarski; Cathy Eng; Eugene J Koay; Bruce D Minsky; Cullen Taniguchi; Sunil Krishnan; Joseph M Herman; Prajnan Das Journal: J Gastrointest Oncol Date: 2017-12